New Parkinson’s disease chemical messenger discovered
News Mar 30, 2014
A new chemical messenger that is critical in protecting the brain against Parkinson’s disease has been identified by scientists at the Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.
The research team led by Dr Miratul Muqit had previously discovered that mutations in two genes – called PINK1 and Parkin – lead to Parkinson’s.
Now they have made a completely unexpected discovery about the way the two genes interact, which they say could open up exciting new avenues for research around Parkinson’s and offer new drug targets. The results of their research are published in Biochemical Journal.
"Understanding the fundamental mechanisms of how brain cells die in Parkinson’s is likely to uncover new insights into how to treat this progressive disorder,” said Dr Muqit, a Wellcome Trust Senior Clinical Fellow and Consultant Neurologist at the MRC Protein Phosphorylation and Ubiquitylation Unit at Dundee.
“Our previous research had mapped out a key pathway involving the PINK1 and Parkin genes that when disrupted by mutations led to Parkinson’s disease. However, we still did not understand the molecular details of how this pathway was controlled.
“Our new work suggests a chemical messenger called phospho-ubiquitin, is protective and can’t be made in Parkinson’s patients with genetic mutations in PINK1. This leaves their brain cells vulnerable to stress and likely to trigger cell death.”
Dr Muqit’s team had already found that the PINK1 and Parkin genes encode for important enzymes that protect brain cells. In patients with mutations in PINK1 and Parkin the protective effects of these enzymes is lost and brain cells controlling movement are damaged, resulting in Parkinson’s.
Previous work revealed that the PINK1 enzyme protects survival of brain cells by switching on Parkin, but how this occurred was unknown and in itself formed a major area of research.
Now they have worked out how the two genes interact. They have uncovered that the role of the PINK1 enzyme is to generate a novel chemical messenger molecule termed `phospho-ubiquitin’.
Their research shows that phospho-ubiquitin then functions to directly switch on the Parkin enzyme.
“The data suggests that phospho-ubiquitin molecules will play a critical role in protecting brain cells and thus patients from developing Parkinson’s disease,” said Dr Muqit.
“This research opens up new exciting avenues for future research that include studying whether low levels of the phospho-ubiquitin molecule are a common feature and cause of Parkinson’s. The new data also suggests that it might be possible to develop drugs to better treat Parkinson’s that can switch on the Parkin enzyme by mimicking phospho-ubiquitin.”
Professor Dario Alessi, Director of the MRC unit at Dundee and a co-author on the study, added, “Now that we have identified this new chemical messenger, it will be important to determine its role in Parkinson’s patients. Whilst more work is needed, our findings suggest that designing drugs that mirror phospho-ubiquitin could represent an exciting approach to develop an urgently needed novel therapy for Parkinson’s patients.”
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Agne Kazlauskaite, Chandana Kondapalli, Robert Gourlay, David G Campbell, Maria Stella Ritorto, Kay Hofmann, Dario R Alessi, Axel Knebel, Matthias Trost, Miratul M.K. Muqit. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Serine65. Biochemical Journal, Published March 25 2014. doi: 10.1042/BJ20140334
The Mouse Brain Can Prioritize Hunger by Suppressing Pain When Survival is at StakeNews
Researchers show that pain and hunger interact in complex ways in mice: extreme hunger suppresses less-urgent inflammatory pain, so that the mice are willing to go find food, but leaves them able to feel and react to more life-and-death kinds of pain.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018